Oncology Pharmacy Specialty Review Course and Workbook Chapters (No Recert Credit) (Cert # L249043)

These activities are intended for pharmacists who are seeking to update their knowledge and skills commensurate with a board certification examination in the areas listed below.

This course consists of 20 activities (see table below) and provides up to 26 contact hours of continuing pharmacy education credit. The Review Course includes case-based presentations for application to real-life scenarios, links to the reference sources, and domains, tasks, and knowledge statements.       

After participating in this CPE activity, learners should be able to: 

ACPE Number: 0204-9999-24-903-H01-P

Adult Acute Leukemias and Myelodysplastic Syndromes

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adults with acute leukemia or myelodysplastic neoplasms.
• Assess the prognostic impact of relevant cancer-related molecular biology testing for an adult with acute leukemia or myelodysplastic neoplasms.
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions from pharmacotherapy for acute leukemia and myelodysplastic neoplasms in an adult, including tumor lysis syndrome, neurotoxicity, differentiation syndrome, and cardiac toxicity from arsenic trioxide, and other agents as appropriate.
• Determine appropriate pharmacotherapy for acute leukemia or myelodysplastic neoplasms in an adult based on genomic test results.

Chronic Leukemias

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration relevant molecular biology testing, genomic information, efficacy and safety outcomes from clinical trials, and current treatment guidelines for patients with chronic leukemia.
• Develop an appropriate plan for preventing, monitoring, and treating infusion-related reactions from monoclonal antibodies used in the treatment of hematologic malignancies.
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for the treatment of cancers, including toxicities from tyrosine kinase inhibitors used to treat hematologic cancers.

Pharmacogenomics in Oncology

• Identify appropriate considerations for genetic interpretation in both the germline and somatic settings utilizing a variety of next generation sequencing techniques.
• Apply the results from germline and somatic genetic testing into therapeutic recommendations based on prognostic, predictive and patient characteristics.
• Recognize the place in therapeutic decision making for companion diagnostic testing.

ACPE Number: 0204-9999-24-904-H01-P

Research Design, Statistics, and Evaluating Oncology Literature

• Evaluate the oncology literature, including study design, identification of sources of bias, methodology, statistical analysis, and applicability of results to clinical practice for the oncology patient population.
• Interpret the validity and results of various types of oncology studies (e.g., meta-analyses, noninferiority trials).
• Interpret findings from the use of study endpoints (e.g., objective response, time to progression, adverse events, quality of life, overall survival) in oncology research.
• Interpret sensitivity, specificity, positive and negative predictive values, measures of effect, correlation, and regression for an oncology study.

Gynecologic Malignancies

• Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes of clinical trials and current treatment guidelines for a patient a with a gynecologic malignancy.
• Discuss short- and long-term goals including post-therapy and survivorship, with a patient with a gynecologic malignancy and her caregiver.
• Select relevant information and provide guidance for the public regarding gynecologic malignancy‐related issues (e.g., risk factors, prevention and screening).

Upper Gastrointestinal and Hepatocellular Carcinomas

• Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with esophageal, gastric, or hepatic malignancies.
• Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer agents used for gastrointestinal malignancies.
• Develop an appropriate plan for preventing, monitoring, and treating radiation recall and other complications of radiation therapy.

ACPE Number: 0204-9999-24-905-H01-P

Breast Cancer

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with breast cancer.
• Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with breast cancer and her or his caregiver.
• Determine appropriate pharmacotherapy for a patient with breast cancer based on genomic test results.
• Identify appropriate diagnostic and prognostic tests related to breast cancer.
• Select relevant information and guidance for the public regarding breast cancer-related issues (e.g., cancer risk factors, prevention, screening).

Multiple Myeloma

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients with multiple myeloma.
• Evaluate oncology pharmacy services for compliance with established REMS regulations and standards.
• Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of cancers, including bone metastases in multiple myeloma patients and thromboembolism, hypercalcemia of malignancy, and spinal cord compression.

ACPE Number: 0204-9999-24-906-H01-P

Oncology Practice Management

• Evaluate oncology pharmacy services for compliance with established regulations, professional practice standards, and procedures for handling, administration, and disposal of hazardous drugs.
• Select quality-improvement activities that enhance the safety and effectiveness of the medication-use processes in oncology patient care.
• Explain methods to optimize medication inventory management for oncology patients.
• Evaluate policies and procedures related to conducting research involving of investigational drugs, including drug management in patients with cancer.

Lymphomas

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan to include effectiveness, toxicities and outcomes, based on the most current guidelines for patients with lymphoma.
• Assess the prognostic impact of relevant cancer-related molecular biology testing.
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lymphoma and other cancers, including chemotherapy-induced pulmonary toxicities and extravasation.

Melanoma and Non-Melanoma Skin Cancers

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with melanoma or non-melanoma skin cancer.
• Discuss short- and long-term goals, including post-therapy and survivorship, with a patient with melanoma or non-melanoma skin cancer and his or her caregiver.
• Select relevant information and guidance for the public regarding melanoma and non-melanoma skin cancer-related issues (e.g., risk factors, prevention, screening).
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of melanoma and non-melanoma skin cancers, including thyroid level monitoring for chemotherapy agents, immune-mediated toxicities, and toxicity from BRAF inhibitors.

ACPE Number: 0204-9999-24-907-H01-P

Lung Cancer

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lung cancer.
• Select relevant information and guidance for the public regarding lung cancer-related issues (e.g., risk factors, prevention, screening).
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lung cancer.
• Develop an appropriate plan for preventing, monitoring, and managing adverse reactions associated with tyrosine kinase inhibitors and mTOR inhibitors.

Head, Neck, Adult Central Nervous System, and Thyroid Cancers

• Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with head, neck, adult central nervous system (CNS), or thyroid cancers.
• Select relevant information and guidance for the public regarding head and neck cancer-related issues (e.g., risk factors, prevention, screening).
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with the treatment of cancers including cancer cachexia, mucositis, and xerostomia.

Bladder, Renal, and Testicular Cancers

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with bladder, renal cell, or testicular carcinomas.
• Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with bladder, renal cell, or testicular carcinomas and his or her caregiver.
• Develop an appropriate plan for preventing, monitoring, and managing QT interval prolongation associated with antineoplastics and oncology supportive care agents.  

ACPE Number: 0204-9999-24-908-H01-P

Hematopoietic Cell Transplantation

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients undergoing hematopoietic cell transplantation (HCT).
• Apply appropriate strategies to prevent and treat toxicity from chemotherapy agents employed in HCT conditioning regimens.
• Create a plan for prevention and management of acute and chronic graft-versus-host disease (GVHD) using appropriate systemic and ancillary therapies.
• Discuss short- and long-term treatment goals, including post-therapy and survivorship, with the patient undergoing HCT and his or her caregiver.

Prostate Cancer

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with prostate cancer.
• Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with prostate cancer and his caregiver.
• Select relevant information and guidance for the public regarding prostate cancer-related issues (e.g., risk factors, prevention, screening).

Lower Gastrointestinal and Pancreatic Cancers

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with lower gastrointestinal (GI) or pancreatic cancers.
• Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient with lower GI or pancreatic cancers and his or her caregiver.
• Select relevant information and guidance for the public regarding lower GI and pancreatic cancer-related issues (e.g., risk factors, prevention, screening).
• Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for lower GI or pancreatic cancers, including chemotherapy-induced diarrhea, hand-foot syndrome, hand foot skin reaction, neurotoxicity from oxaliplatin, and dermatologic toxicities from epidermal growth factor receptor inhibitors.

ACPE Number: 0204-9999-24-909-H01-P

Pediatric Malignancies and Supportive Care

• Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for pediatric patients with cancer.
• Assess the prognostic impact of relevant cancer-related molecular biology testing for a pediatric patient with cancer.
• Discuss with a pediatric patient who has cancer and his or her caregiver the short- and long-term treatment goals, including post-therapy and survivorship.
• Assess the regulatory, ethical, and patient rights issues related to conducting research, including informed consent and confidentiality.

Cancer-related Infectious Diseases

• Design an appropriate patient-specific management and monitoring plan to address potential infection-related problems that may arise during and following cancer treatment based on current guidelines for treating cancer-related infectious diseases.
• Discuss short- and long-term treatment goals, including post-therapy, with a patient with cancer-related infectious disease and his or her caregiver.

Adult Sarcomas

• Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adult patients with sarcoma.
• Adjust treatment and monitoring plans as needed based on tumor genetics and pharmacokinetics of anticancer and supportive-care agents (e.g., methotrexate).
• Develop an appropriate plan for preventing, monitoring and managing common problems associated with the treatment of adult patients with cancer including neurotoxicity from ifosfamide and hemorrhagic cystitis.

Full Faculty Bios

Jessica Auten, PharmD, BCOP
Clinical Pharmacy Specialist, Malignant Hematology
University of North Carolina Medical Center
Assistant Professor of Clinical Education
UNC Eshelman School of Pharmacy
Chapel Hill, North Carolina 

John Bossaer, PharmD, BCOP
Professor
ETSU Bill Gatton College of Pharmacy
Johnson City, Tennessee 

Ryan Bycroft, PharmD, BCOP
Clinical Oncology Pharmacist
University of Louisville Hospital, Brown Cancer Center
Louisville, Kentucky 

Courtney C. Cavalieri, PharmD, BCOP*
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah 

Brette Conliffe, PharmD, BCOP
Clinical Oncology Pharmacy Supervisor
University of Louisville Health/Brown Cancer Center
Louisville, Kentucky 

Karen M. Fancher, PharmD, BCOP*
Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Clinical Pharmacy Specialist, Oncology
University of Pittsburgh Medical Center Passavant
Pittsburgh, Pennsylvania 

Christopher Fausel, PharmD, MHA, BCOP
Director of Pharmacy Precision Genomics
Indiana University Health
Chairman of the Board
Hoosier Cancer Research Network
Indianapolis, Indiana 

Lauren Ice, PharmD, BCOP, BCPS
Clinical Pharmacy Specialist
Corewell Health
Grand Rapids, Michigan

Alexis R. Jones, PharmD, BCOP, CPP
Clinical Pharmacist, Gynecologic Oncology
University of North Carolina Medical Center
Chapel Hill, North Carolina 

Elyse A. MacDonald, PharmD, MS, BCPS
Director, Investigational Drug Service
Stanford Health Care
Palo Alto, California 

Janelle Mann, PharmD, BCOP
Manager of Clinical Pharmacy Services/Clinical Oncology Pharmacist
Washington University School of Medicine/Siteman Cancer Center
St. Louis, Missouri 

Colleen McCabe, PharmD, BCOP
Clinical Oncology Pharmacy Specialist, Sarcoma and Melanoma
Vanderbilt University Medical Center
Nashville, Tennessee 

Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP
Clinical Oncology Pharmacy Manager
Levine Cancer Institute
Charlotte, North Carolina 

Anthony J. Perissinotti, PharmD, BCOP*
Hematology Clinical Pharmacist Specialist
University of Michigan
Ann Arbor, Michigan 

Danielle Roman, PharmD, BCOP
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania 

Christine M. Walko, PharmD, BCOP, FCCP*
Senior Member, Individualized Cancer Management, Precision Medicine Team Lead
Moffitt Cancer Center
Tampa, Florida 

Jennifer Young, PharmD, BCOP
Clinical Pharmacy Specialist – Pediatric Hematology/Oncology
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio 

*Content Matter Experts

Jaime Anderson, PharmD, BCOP, CMQ
Justin Arnall, PharmD, BCOP
Christine Barrett, PharmD, BCOP
Allison Bass, PharmD, BCOP
Miranda Benfield, PharmD, BCOP
Colleen Bohnenkamp, PharmD, BCOP, BCPS
Melissa Bourque, PharmD, BCPS, BCOP
Janet Bramell, PharmD, BCPS, BCOP
Amelia Chan, PharmD, MBA, MS, BCOP
Alexis Chapman, PharmD, BCOP
Jill Comeau, PharmD, BCOP
Bryna Delman Ewachiw, PharmD, BCOP
Katie Gaches, PharmD, BCOP
Brent Harris, PharmD, MBA, BCPS, BCOP
Michael Hebert, PharmD, BCPS, BCOP
Scott Heinemann, PharmD, BCOP
Shahrier Hossain, Pharm.D, BCOP
Mitchell Hughes, PharmD,BCOP
Mark Jao, PharmD, BCOP
Patricia Jeppson, PharmD, BCOP
Elizabeth Kelley, PharmD, BCOP, BCPS
Abby Kim, PharmD, BCOP
Chung-Shien Lee, PharmD, BCPS, BCOP
Katherine Lin, PharmD, BCOP
Andrea Lippucci, PharmD, BCPS, BCOP, CPP
Morgan Mace, PharmD, BCOP
Catherine Martin, PharmD, BCOP
Megan May, PharmD, BCOP, FHOPA, FAPO
Megan Mullalley, PharmD, BCOP, BCPS
Caitlin Rausch, PharmD, BCPS
Josh Reardon, PharmD, BCOP
Teresa Rushing, PharmD, BCPS, BCOP
Katherine Saunders, PharmD, BCOP
Kelsea Seago, PharmD, BCOP
Shreya Shah, PharmD, BCOP
Jennifer Tobin, PharmD, BCOP
Katelyn Toeniskoetter, PharmD, BCOP
Jaelyn Westfield, PharmD, BCOP
Lily Yan, PharmD, BCOP
Deidre Yarosh, PharmD, MA, BCOP
Mark Zangardi, PharmD, MS, BCOP

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

The following persons in control of this activity’s content have relevant financial relationships:

• Anthony J. Perissinotti: Consultant and Advisory Board Member, Pfizer, BeiGene, Sanofi Aventis; Advisory Board Member, Janssen, Abbvie
• Alexis Jones: Multidisciplinary Council Member, Esai
• Colleen McCabe: Advisory Board Member, Daichi Sankyo
• Courtney Cavalieri: Consultant, Pfizer
• Karen M. Fancher: Consultant, BTG Specialty Pharmaceuticals; Consultant, AstraZeneca Pharmaceuticals LP
• Mitchell Hughes: Consulting Advisory Board, Sanofi Aventis; Research Grant, Acerta Pharma; Pharmacy Consultant, AstraZeneca
• Donald Moore: Advisory Board Member, Janssen
• Danielle Roman: Advisory Board Member, Daiichi Sankyo
• Shreya Shah: Advisor, Incyte
• Deirdre Yarosh: Research grant, Pfizer; Advisory Board, Janssen
• Shahrier Hossain: Advisory Board Member, Janssen
• Teresa Rushing: Advisory Board Member, Jazz Pharmaceuticals

All other planners, presenters, reviewers, ASHP staff, and others with an opportunity to control content report no financial relationships relevant to this activity.

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

ASHP and ACCP collaborate on oncology activities. 

To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations.